BioTime (NYSEAMERICAN:BTX) released its earnings results on Thursday. The biotechnology company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01), Morningstar.com reports. The business had revenue of $0.98 million during the quarter, compared to the consensus estimate of $0.75 million.
Shares of NYSEAMERICAN BTX opened at $1.92 on Friday. BioTime has a 12-month low of $1.80 and a 12-month high of $3.16.
Separately, Zacks Investment Research downgraded BioTime from a “buy” rating to a “hold” rating in a report on Wednesday, October 3rd.
ILLEGAL ACTIVITY WARNING: “BioTime (BTX) Announces Earnings Results” was first published by WKRB News and is owned by of WKRB News. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.wkrb13.com/2018/11/10/biotime-btx-announces-earnings-results.html.
BioTime Company Profile
BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.
Further Reading: Insider Trading – What You Need to Know
Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.